A single pathophysiological pathway in Takotsubo cardiomyopathy: Catecholaminergic stress
Related Experiment Video
Updated: Apr 30, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
Elisabeth Coupez1, Romain Eschalier1, Bruno Pereira2
1Department of Cardiology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France; UMR 6284 CNRS-ISIT, Auvergne University, Clermont-Ferrand, France.
Insights
Takotsubo cardiomyopathy (TTC) is consistently linked to catecholaminergic stress, irrespective of the initial trigger. Early diagnosis and treatment of TTC, often presenting as thoracic pain, lead to excellent cardiovascular recovery.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Pharmacology
Background:
- Takotsubo cardiomyopathy (TTC) is frequently underdiagnosed due to varied presentations.
- Delayed treatment for TTC can lead to severe complications.
Purpose of the Study:
- To establish the consistent role of catecholaminergic stress in TTC.
- To investigate TTC regardless of the specific trigger.
Main Methods:
- Prospective follow-up of patients with thoracic pain syndrome.
- Diagnosis of TTC via left ventricular imaging in the absence of coronary artery disease.
- Assessment of triggers including emotional trauma, surgical stress, and β2-mimetic intoxication; screening for catecholamine-secreting tumors.
Main Results:
- TTC was diagnosed in 1.5% of patients with thoracic pain.
- Emotional trauma was the most common trigger (72.5%), followed by surgical stress (12.5%).
- Initial presentation included cardiogenic shock in 20% of patients, with a 7.5% in-hospital mortality rate.
Conclusions:
- Catecholaminergic stress is the unifying factor in TTC, regardless of the trigger.
- TTC can be induced by emotional trauma, surgical stress, or β2-mimetic intoxication.
- Early treatment of TTC is associated with an excellent cardiovascular prognosis.
Background:
Takotsubo cardiomyopathy (TTC) continues to be under-diagnosed, due to its varying presentation, with potentially serious consequences if treatment is delayed.
Aims:
To demonstrate the consistent involvement of catecholaminergic stress in TTC, regardless of the trigger.
Methods:
Between 01 July 2009 and 31 August 2013, patients managed in our centre for thoracic pain syndrome, with or without troponin release, were followed up prospectively. TTC was diagnosed from the apical ballooning seen on left ventricular imaging (angiography or transthoracic echocardiography) in the absence of a significant coronary artery lesion. Triggers (emotional trauma, surgical stress and β2-mimetic intoxication) were recorded; catecholamine-secreting tumours were screened for with a urinary methoxylate-derivative assay.
Results:
TTC was diagnosed in 40 out of 2754 (1.5%) patients with thoracic pain syndrome, with or without troponin release. Triggers were emotional trauma (n=29, 72.5%), surgical stress (n=5, 12.5%), adrenergic intoxication (n=3, 7.5%) and catecholaminergic tumour (n=3, 7.5%). Mean left ventricular ejection fraction at admission was 38.0 ± 15.7%. Eight (20%) patients initially showed cardiogenic shock. In-hospital mortality was 7.5%, with no deaths from cardiogenic causes. Thirty-five (94.6%) of the survivors had recovered a normal left ventricular ejection fraction (> 55%) by discharge.
Conclusion:
Whatever the trigger, the common denominator in TTC is catecholaminergic stress. Classically suggested after emotional trauma, TTC may also be induced by surgical stress or endogenous or iatrogenic β2-mimetic intoxication. The various contexts all have a similarly excellent cardiovascular prognosis if treated early.
Related Concept Videos
Heart Failure II: Pathophysiology
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Pathophysiology of Heart Failure
Physiological Foundation of Stress
Role of the Sympathetic Nervous System
Adrenaline triggers the...
Coronary Artery Disease II: Pathophysiology

